Analyze Diet
Voprosy virusologii1993; 38(5); 222-226;

[The immunogenic properties of a recombinant vaccinia virus with an incorporated DNA copy of the 26S RNA of the Venezuelan equine encephalomyelitis virus].

Abstract: A recombinant strain of vaccinia virus (VR26) containing a DNA-copy of the subgenomic 26S RNA of Venezuelan equine encephalomyelitis virus (VEE) inserted into the coding region of thymidine kinase (TK) gene was produced. This subgenomic RNA contained the genes for all structural proteins of the VEE virus, the strain Trinidad donkey (TRD). VR26 effectively expressed VEE virus glycoproteins on the membranes of the infected cells. Blood sera of VR26-immunized animals were found to contain VEE virus-specific antibodies. VR26-immunized mice and rabbits showed a high level of resistance to subcutaneous inoculation with the pathogenic TRD strain of VEE virus. VR26 also provided a high level of protection in animals against aerogenic infection. The absence of virus-neutralizing antibodies in most VR26-immunized animals resistant to inoculation with high doses of VEE suggests the dominant role of the cell component in the immune response. The immune response induced by the recombinant VR26 strain was stable as demonstrated by the resistance of the animals to a challenge with VEE virus 7 months after immunization. The experimental results suggest that this recombinant strain may be considered as a candidate for vaccine preparation.
Publication Date: 1993-09-01 PubMed ID: 8284922
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • English Abstract
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This study explores the development and testing of a recombinant vaccinia virus, termed VR26, containing a DNA copy of the structural proteins of Venezuelan equine encephalomyelitis virus (VEE). Results indicate that the VR26 immunization induces a strong immune response against VEE infection, making it a potential candidate for vaccine development.

Creation of VR26

  • The researchers developed a modified vaccinia virus named VR26. This was a recombinant virus, meaning that it was genetically engineered to include a DNA copy of another virus’s RNA.
  • The RNA that they chose to incorporate was the 26S RNA of Venezuelan equine encephalomyelitis virus (VEE). Specifically, this was subgenomic RNA, which referenced the genes for all the structural proteins of the VEE virus, from the strain known as Trinidad donkey (TRD).
  • The inserted RNA was integrated into the coding region of the vaccinia virus’s thymidine kinase (TK) gene, a crucial component of the virus’s replication process.

Expression of VEE Virus Glycoproteins

  • This study demonstrated that after infection with VR26, there was effective expression of VEE virus glycoproteins on the infected cells’ membrane surfaces.
  • This is significant from an immunology standpoint, as these glycoproteins are key to the ability of the VEE virus to enter host cells.

Induction of VEE Virus-Specific Antibodies

  • The research found that animals immunized with VR26 produced blood serum containing VEE virus-specific antibodies, indicating recognition of and response to the VEE virus.
  • Mice and rabbits who received VR26 immunization demonstrated significantly increased resistance to subcutaneous inoculation with the TRD strain of the VEE virus.

Protection Against Aerogenic Infection

  • Significantly, VR26 also proved to provide high levels of protection against aerogenic infection, where the virus was delivered via the respiratory route.
  • Despite most VR26-immunized animals not exhibiting virus-neutralizing antibodies, they still demonstrated resistance to high doses of VEE virus. These findings suggest the presence of a dominant, cell-based component in the immune response to VEE virus.

Stable Immune Response

  • The study indicated this immune response was stable over time, with animals still demonstrating resistance to a VEE virus challenge seven months after initial VR26 immunization.
  • The stable response and high level of induced immunity suggest the potential for the VR26 recombinant strain to be used in vaccine preparation.

Cite This Article

APA
Sviatchenko VA, Agapov EV, Urmanov IKh, Serpinskiĭ OI, Frolov IV, Kolykhalov AA, Ryzhikov AB, Netesov SV. (1993). [The immunogenic properties of a recombinant vaccinia virus with an incorporated DNA copy of the 26S RNA of the Venezuelan equine encephalomyelitis virus]. Vopr Virusol, 38(5), 222-226.

Publication

ISSN: 0507-4088
NlmUniqueID: 0417337
Country: Russia (Federation)
Language: rus
Volume: 38
Issue: 5
Pages: 222-226

Researcher Affiliations

Sviatchenko, V A
    Agapov, E V
      Urmanov, I Kh
        Serpinskiĭ, O I
          Frolov, I V
            Kolykhalov, A A
              Ryzhikov, A B
                Netesov, S V

                  MeSH Terms

                  • Animals
                  • DNA, Complementary / genetics
                  • DNA, Viral / genetics
                  • Encephalitis Virus, Venezuelan Equine / genetics
                  • Encephalomyelitis, Venezuelan Equine / immunology
                  • Encephalomyelitis, Venezuelan Equine / prevention & control
                  • Gene Expression Regulation, Viral / genetics
                  • Gene Expression Regulation, Viral / immunology
                  • Immune Sera / immunology
                  • Immunization / methods
                  • Mice
                  • RNA, Messenger / genetics
                  • RNA, Ribosomal / genetics
                  • RNA, Viral / genetics
                  • Rabbits
                  • Recombination, Genetic / genetics
                  • Recombination, Genetic / immunology
                  • Time Factors
                  • Vaccinia / immunology
                  • Vaccinia / prevention & control
                  • Vaccinia virus / genetics
                  • Vaccinia virus / immunology

                  Citations

                  This article has been cited 3 times.
                  1. Weger-Lucarelli J, Chu H, Aliota MT, Partidos CD, Osorio JE. A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice.. PLoS Negl Trop Dis 2014 Jul;8(7):e2970.
                    doi: 10.1371/journal.pntd.0002970pubmed: 25058320google scholar: lookup
                  2. Kim DY, Atasheva S, Foy NJ, Wang E, Frolova EI, Weaver S, Frolov I. Design of chimeric alphaviruses with a programmed, attenuated, cell type-restricted phenotype.. J Virol 2011 May;85(9):4363-76.
                    doi: 10.1128/JVI.00065-11pubmed: 21345954google scholar: lookup
                  3. Gorchakov R, Volkova E, Yun N, Petrakova O, Linde NS, Paessler S, Frolova E, Frolov I. Comparative analysis of the alphavirus-based vectors expressing Rift Valley fever virus glycoproteins.. Virology 2007 Sep 15;366(1):212-25.
                    doi: 10.1016/j.virol.2007.04.014pubmed: 17507072google scholar: lookup